These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206 [TBL] [Abstract][Full Text] [Related]
3. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior. Tornóczky T; Kálmán E; Kajtár PG; Nyári T; Pearson AD; Tweddle DA; Board J; Shimada H Cancer; 2004 Jan; 100(2):390-7. PubMed ID: 14716776 [TBL] [Abstract][Full Text] [Related]
5. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100 [TBL] [Abstract][Full Text] [Related]
6. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322 [TBL] [Abstract][Full Text] [Related]
7. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152 [TBL] [Abstract][Full Text] [Related]
8. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748 [TBL] [Abstract][Full Text] [Related]
9. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. Navarro S; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Mosseri V; De Bernardi B; Michon J; Peuchmaur M; J Clin Oncol; 2006 Feb; 24(4):695-9. PubMed ID: 16446343 [TBL] [Abstract][Full Text] [Related]
11. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas. Zhang J; Zheng Y; Wang Y; Tong H J Pediatr Hematol Oncol; 2010 Apr; 32(3):180-4. PubMed ID: 20186105 [TBL] [Abstract][Full Text] [Related]
12. The International Neuroblastoma Pathology Classification (the Shimada system). Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B; Stram DO; Gerbing RB; Lukens JN; Matthay KK; Castleberry RP Cancer; 1999 Jul; 86(2):364-72. PubMed ID: 10421273 [TBL] [Abstract][Full Text] [Related]
13. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Tang XX; Evans AE; Zhao H; Cnaan A; Brodeur GM; Ikegaki N Med Pediatr Oncol; 2001 Jan; 36(1):80-2. PubMed ID: 11464911 [TBL] [Abstract][Full Text] [Related]
14. [Pathology of peripheral neuroblastic tumors]. Wang L; He LJ; Shimada H Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533 [No Abstract] [Full Text] [Related]
15. MYCN protein expression as a predictor of neuroblastoma prognosis. Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553 [TBL] [Abstract][Full Text] [Related]
16. Surgical aspects of N-myc oncogene amplification of neuroblastoma. Nakagawara A; Ikeda K; Yokoyama T; Tsuda T; Higashi K Surgery; 1988 Jul; 104(1):34-40. PubMed ID: 3388178 [TBL] [Abstract][Full Text] [Related]
17. The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors. de Torres C; Beleta H; Díaz R; Toran N; Rodríguez E; Lavarino C; García I; Acosta S; Suñol M; Mora J Cancer; 2009 Jun; 115(12):2792-803. PubMed ID: 19350667 [TBL] [Abstract][Full Text] [Related]
18. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data. Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823 [TBL] [Abstract][Full Text] [Related]
19. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Peuchmaur M; d'Amore ES; Joshi VV; Hata J; Roald B; Dehner LP; Gerbing RB; Stram DO; Lukens JN; Matthay KK; Shimada H Cancer; 2003 Nov; 98(10):2274-81. PubMed ID: 14601099 [TBL] [Abstract][Full Text] [Related]
20. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Tang XX; Evans AE; Zhao H; Cnaan A; London W; Cohn SL; Brodeur GM; Ikegaki N Clin Cancer Res; 1999 Jun; 5(6):1491-6. PubMed ID: 10389937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]